Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Leukemia 10Recurrence 9Lymphoproliferative Disorders 6Neoplasm, Residual 5Lymphatic Diseases 5Burkitt Lymphoma 5Lymphoma, Non-Hodgkin 4Immunoproliferative Disorders 4Neoplasms 3Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Leukemia, Lymphoid 2Bites and Stings 2Neoplasms by Histologic Type 1Lymphoma 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Blast Crisis 1

Interventions

nilotinib 4Imatinib Mesylate 4Dasatinib 4troxacitabine 1ponatinib 1litronesib 1exatecan 1carfilzomib 1bosutinib 1blinatumomab 1asciminib 1TAK-901 1STA 9090 1Panobinostat 1Homoharringtonine 1Fentanyl 1Dexamethasone 1Decitabine 1Calcium Dobesilate 12-(2-oxo-2-((3,7,11-trimethyl-2,6,10-dodecatrienyl)oxy)aminoethyl)phosphonic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester sodium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Blast Crisis × blinatumomab × Clear all
NCT04260022 2025-11-05

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

Ascentage Pharma Group Inc.

Phase 1 Recruiting
242 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Burkitt Lymphoma, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡